| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
In SH-SY5Y cells, AM281 (0.01-10 μM) causes neurotoxicity at concentrations that raise the presence of 10 μM Aβ 25-35 when combined with 10 μM KSO 1-6 [2].
|
|---|---|
| ln Vivo |
Both the chronic doses of AM281 (0.62, 1.25, and 2.5 mg/kg) and the chronic doses of AM281 (2.5, 5 and 10 mg/kg) showed improvements in memory performance and exploration time [3]. The recognition index was increased to 22.1±4.8 with long-term administration of 2.5 mg/kg AM281, and memory impairment was improved to 8.5±4 with a single dosage of 5 mg/kg AM281, as opposed to 4.8±2.5 with vehicle therapy. AM281 given continuously at a dose of 2.5 mg/kg and
|
| Animal Protocol |
Animal/Disease Models: Male NMRI mice weighing 25-30 g [3] Doses: 0.62, 1.25 and 2.5 mg/kg (chronic dose); rapid dose of 5 mg/kg Can improve memory[3]. 2.5, 5 and 10 mg/kg (acute administration) Dosing: intraperitoneally (ip) (ip) with morphine daily except on the day of the experiment (chronic administration); alone 40 minutes before the second test (acute administration)
Experimental Results: Coadministration of AM281 and morphine daily Dramatically shortened exploration time compared to morphine-dependent mice receiving vehicle. The acute administration dose is 5 mg/kg, and the recognition index is Dramatically enhanced. |
| References |
|
| Additional Infomation |
1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(4-morpholinyl)-3-pyrazolecarboxamide is a member of pyrazoles and a ring assembly.
|
| Molecular Formula |
C21H19N4O2CL2I
|
|---|---|
| Molecular Weight |
557.21116
|
| Exact Mass |
555.993
|
| CAS # |
202463-68-1
|
| PubChem CID |
4302962
|
| Appearance |
White to light yellow solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
30
|
| Complexity |
589
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(N(N=C1C(NN2CCOCC2)=O)C3=C(Cl)C=C(Cl)C=C3)C4=CC=C(I)C=C4
|
| InChi Key |
AJFFBPZYXRNAIC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H19Cl2IN4O2/c1-13-19(21(29)26-27-8-10-30-11-9-27)25-28(18-7-4-15(22)12-17(18)23)20(13)14-2-5-16(24)6-3-14/h2-7,12H,8-11H2,1H3,(H,26,29)
|
| Chemical Name |
1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-morpholin-4-ylpyrazole-3-carboxamide
|
| Synonyms |
AM 281 AM-281 AM281
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~7.14 mg/mL (~12.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.71 mg/mL (1.27 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 7.1 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7947 mL | 8.9733 mL | 17.9466 mL | |
| 5 mM | 0.3589 mL | 1.7947 mL | 3.5893 mL | |
| 10 mM | 0.1795 mL | 0.8973 mL | 1.7947 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
